Nestlé Institute of Health Sciences (NIHS, Lausanne, Switzerland), has licensed technology from ViaCyte, Inc., for basic research purposes
SAN DIEGO, March 12, 2012. The license agreement provides access to ViaCyte’s cell engineering technologies to support the Institute’s research programs developing personalized solutions for maintaining health and preventing diseases. In particular, this agreement will allow the Nestlé Institute of Health Sciences to develop models of human pancreatic cells and tissues. Nestlé Institute of Health Sciences will not use human embryonic stem cells but induced pluripotent stem cells (iPSCs) to study the molecular processes governing the progression from health to disease for diabetes. The technologies are licensed from ViaCyte on a non-exclusive basis and also have a wide application to multiple additional areas of the Institute’s focus such as Metabolic Health, Gastro-intestinal Health and Brain Health. For more information on the Institute please see www.nestleinstitutehealthsciences.com.